- Conditions
- Asthma
- Interventions
- Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 776 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 50
- States / cities
- Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 216
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Interventions
- busulfan, cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Liver Diseases, Alcoholic, Alcoholism, HIV, Hepatitis C
- Interventions
- Integrated Stepped Care (ISC), Treatment as Usual
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • New York, New York + 2 more
- Conditions
- Obesity
- Interventions
- mental contrasting with implementation intentions, telephone-delivered, telehealth-delivered, and or in-person MOVE! or TeleMOVE!, Information About Diet, Physical Activity, and Weight Management (Baseline Visit - 10 minutes): All, Telephone MCII Check-ins (30 minutes at 3 days, 4 weeks, and 2 months after baseline visit)
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 405 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Asthma
- Interventions
- Antipyrine-benzocaine otic solution, Glycerin with Oxyquinoline Sulfate
- Drug · Other
- Lead sponsor
- Global United Pharmaceutical Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Once-daily aclidinium/formoterol, Twice-daily formoterol fumarate, Placebo to formoterol fumarate, Once-daily formoterol fumarate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Fullerton, California • Lakewood, California + 36 more
- Conditions
- Alcohol Use, Alcohol Drinking, Drinking Behavior
- Interventions
- Alcohol-related mobile health technologies, Motivational interview and psychoeducation on blood/breath alcohol concentration, Lower tech facilitation
- Device · Behavioral
- Lead sponsor
- Northeastern University
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cardiovascular Disease (CVD), Hypertension, Hyperlipemia, Obesity
- Interventions
- Community-based peer health coach intervention
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- Up to 75 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Alcohol Drinking, Binge Drinking, Blood Pressure, Alcohol Abstinence, Aging, Lifestyle Factors, Vasodilation, Behavioral Problem
- Interventions
- Exercise Training, Alcohol Abstinence Intervention
- Behavioral
- Lead sponsor
- The University of Texas at Arlington
- Other
- Eligibility
- 50 Years to 64 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Arlington, Texas
- Conditions
- Asthma
- Interventions
- GSK3772847, Placebo, Fluticasone propionate/salmeterol, Fluticasone propionate
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Scottsboro, Alabama • Bakersfield, California + 24 more
- Conditions
- Healthy Volunteer, Alcohol Consumption
- Interventions
- Alcohol (Ethanol)
- Other
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Denton, Texas • San Antonio, Texas
- Conditions
- Atherosclerosis, Endothelial Function
- Interventions
- Nebivolol, Atenolol
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years to 79 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Hypertension
- Interventions
- Nebivolol and Atenolol
- Drug
- Lead sponsor
- Mylan Bertek Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis
- Interventions
- Busulfan, Cytarabine, Fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
- Drug · Procedure · Radiation
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- Up to 69 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Prevention Harmful Effects
- Interventions
- computer-facilitated brief intervention
- Behavioral
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 9 Years to 18 Years
- Enrollment
- 871 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • East Boston, Massachusetts • Lexington, Massachusetts
- Conditions
- Alcohol Use Disorder
- Interventions
- Sunobinop, Placebo to match sunobinop
- Drug
- Lead sponsor
- Knoa Pharma LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- PT003 MDI, PT005 MDI, Placebo MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®), Formoterol Fumarate 12 μg (Foradil® Aerolizer®), PT001 MDI
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 4
- States / cities
- Clearwater, Florida • Charlotte, North Carolina • Medford, Oregon + 1 more
- Conditions
- Leukemia
- Interventions
- cyclophosphamide, cyclosporine, etoposide, methotrexate, allogeneic bone marrow transplantation, Total Body Irradiation, Busulfan, Mesna, Radiation
- Drug · Procedure · Radiation
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2001
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • San Diego, California • Jacksonville, Florida + 11 more
- Conditions
- Hepatic Impairment
- Interventions
- Aramchol free acid tablet 600mg, single dose, Aramchol free acid tablet 300mg, bid
- Drug
- Lead sponsor
- Galmed Research and Development, Ltd.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Knoxville, Tennessee
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Indacaterol, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 69
- States / cities
- Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 63 more
- Conditions
- Obesity and Obesity-related Medical Conditions
- Interventions
- Lifestyle Coaching
- Behavioral
- Lead sponsor
- Cambridge Health Alliance
- Other
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Sommerville, Massachusetts
- Conditions
- Survivors of Childhood Cancer, Substance Use
- Interventions
- WHO ASSIST v3.1 Screening with Feedback, ASSIST Linked Brief Intervention (10 Step Motivational interviewing (MI)/FRAMES), WHO ASSIST v3.1 Screening (No Feedback)
- Behavioral
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Lymphoproliferative Disorder, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent High Risk Myelodysplastic Syndrome, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Pharmacological Study, Tacrolimus, Thiotepa
- Procedure · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Respiratory Depression
- Interventions
- Fentanyl
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama